FY2026 Earnings Forecast for Alumis Issued By HC Wainwright

Alumis logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright lowered its FY2026 EPS forecast for Alumis to a loss of $3.04 per share from $2.96, while maintaining a Buy rating and $9 price target. It also projects a $3.14-per-share loss for FY2027.
  • Alumis reported a quarterly loss of $0.73 per share, slightly better than analysts’ $0.76 estimate, and revenue of $1.91 million, just above consensus.
  • Shares were down 8.2% and opened at $5.14, near the stock’s 12-month low of $5.00. Analysts’ consensus rating remains Moderate Buy, with a $31.27 average price target.
  • MarketBeat previews top five stocks to own in December.

Alumis Inc. (NASDAQ:ALMS - Free Report) - Equities research analysts at HC Wainwright lowered their FY2026 earnings per share estimates for Alumis in a research note issued to investors on Friday, November 13th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($3.04) per share for the year, down from their previous estimate of ($2.96). HC Wainwright currently has a "Buy" rating and a $9.00 target price on the stock. The consensus estimate for Alumis' current full-year earnings is ($2.95) per share. HC Wainwright also issued estimates for Alumis' Q4 2026 earnings at ($0.77) EPS, Q1 2027 earnings at ($0.79) EPS, Q2 2027 earnings at ($0.81) EPS, Q3 2027 earnings at ($0.82) EPS, Q4 2027 earnings at ($0.72) EPS and FY2027 earnings at ($3.14) EPS.

A number of other research analysts also recently issued reports on the stock. Guggenheim downgraded shares of Alumis from a "buy" rating to a "neutral" rating in a research report on Thursday, September 3rd. Morgan Stanley dropped their target price on shares of Alumis from $39.00 to $29.00 and set an "overweight" rating for the company in a research report on Wednesday, September 2nd. Oppenheimer cut their target price on shares of Alumis to $28.00 and set an "outperform" rating on the stock in a research note on Monday. Benchmark reiterated a "buy" rating on shares of Alumis in a research report on Monday, October 5th. Finally, Citigroup reissued an "overweight" rating on shares of Alumis in a research note on Tuesday, September 1st. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Alumis currently has a consensus rating of "Moderate Buy" and a consensus target price of $31.27.

Get Our Latest Report on ALMS

Alumis Stock Down 8.2%

NASDAQ:ALMS opened at $5.14 on Tuesday. The stock has a market cap of $665.27 million, a P/E ratio of -1.46 and a beta of -0.28. The firm's fifty day simple moving average is $7.12 and its 200 day simple moving average is $20.35. Alumis has a twelve month low of $5.00 and a twelve month high of $31.35.

Alumis (NASDAQ:ALMS - Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.73) EPS for the quarter, beating analysts' consensus estimates of ($0.76) by $0.03. Alumis had a negative return on equity of 86.62% and a negative net margin of 5,844.54%. The company had revenue of $1.91 million during the quarter, compared to the consensus estimate of $1.90 million.

Insider Buying and Selling at Alumis

In related news, Director Srinivas Akkaraju sold 96,131 shares of Alumis stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $10.55, for a total transaction of $1,014,182.05. Following the sale, the director directly owned 2,025,493 shares in the company, valued at $21,368,951.15. The trade was a 4.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold 99,754 shares of company stock worth $1,037,804 in the last 90 days. Insiders own 33.70% of the company's stock.

Hedge Funds Weigh In On Alumis

A number of institutional investors have recently added to or reduced their stakes in the company. Aquatic Capital Management LLC purchased a new stake in shares of Alumis in the 3rd quarter worth about $783,000. Goldman Sachs Group Inc. increased its stake in shares of Alumis by 10.6% in the 3rd quarter. Goldman Sachs Group Inc. now owns 919,762 shares of the company's stock worth $6,797,000 after acquiring an additional 87,865 shares in the last quarter. Samsara Biocapital LLC lifted its position in Alumis by 14.0% during the 3rd quarter. Samsara Biocapital LLC now owns 7,235,809 shares of the company's stock valued at $53,473,000 after acquiring an additional 890,590 shares during the period. Bellevue Group AG purchased a new position in Alumis during the 3rd quarter valued at about $63,000. Finally, Marshall Wace LLP lifted its position in Alumis by 188.7% during the 3rd quarter. Marshall Wace LLP now owns 1,062,571 shares of the company's stock valued at $7,852,000 after acquiring an additional 694,557 shares during the period.

Recent Alumis Headlines

These are some of the ALMS headlines that stood out recently:

  • Positive Sentiment: Oppenheimer maintained its “Outperform” rating despite reducing its price target to $28 from $37. HC Wainwright also reiterated its “Buy” rating and $9 target. Oppenheimer price target report
  • Neutral Sentiment: Oppenheimer said Alumis’ path is narrowing despite a promising profile, suggesting potential remains but may depend on a more limited route forward. Oppenheimer analysis
  • Negative Sentiment: HC Wainwright lowered its estimates for FY2026 EPS to ($3.04) from ($2.96) and FY2027 EPS to ($3.14) from ($2.91), as well as reducing forecasts across individual quarters. These deeper projected losses may weigh on sentiment; the firm’s FY2027 estimate is also below the reported current-year consensus of ($2.95). HC Wainwright estimates

Alumis Company Profile

(Get Free Report)

Alumis is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases. The company uses data and computational tools to support the discovery and development of targeted treatments. Its lead investigational program, ESK-001, is an oral, selective TYK2 inhibitor being studied for conditions including plaque psoriasis and systemic lupus erythematosus. Alumis is also advancing other drug candidates for immune-mediated diseases. These medicines remain in clinical development and are not approved for commercial use.

Featured Stories

Earnings History and Estimates for Alumis (NASDAQ:ALMS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Alumis Right Now?

Before you consider Alumis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.

While Alumis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines